Dr. Alla Reznik
Receive the latest news, event invites, funding opportunities and more from the Ontario Institute for Cancer Research.
Dr. Reznik and her research group have pioneered solid-state modular PET detector technology, featuring a novel type of four-sided, tileable sensor module. This innovative sensor module design enables seamless connection of the required number of modules, allowing for the creation of sensor areas tailored to the specific size and shape demands of various clinical applications. When combined with advanced solid-state detector components, this innovation significantly enhances detector sensitivity.
In clinical trials, the application of this cutting-edge organ-targeted PET technology, particularly in breast imaging, demonstrated remarkable capabilities in cancer identification, even when using a dosage ten times lower than the standard whole-body PET dose. This improvement in the detectability of small lesions is further complemented by reduced image acquisition times compared to conventional PET technology. These advancements play a pivotal role in making organ-specific PET both cost-effective and accessible for routine clinical use.
Dr. Reznik has successfully transitioned this technology into a patented and FDA-approved clinical diagnostic system, which is now commercially available through Radialis in Ontario, Canada.
Collaboration forms the foundation of Dr. Reznik’s research, which encompasses physics, medical physics, material science, electrical engineering, and clinical studies. In this multidisciplinary setting, the convergence of experts from various domains is vital for driving impactful research and development. This includes forging close partnerships with clinical experts, whose insights and direct engagement effectively connect innovative concepts with tangible healthcare solutions.
